Pancreaticum neuroendocrine tumores (rete), plerumque crescere lente, et officinarum probat ex imagine, per incrementum of monitors in signa tumoris. Net aegris symptomata ut plerumque alvum fusus pancreatis hormonalis vel elit. Quia non potest esse medicinae ut octreotide, lanreotide, diazoxide et protón sentinam inhibitors, quod potest inhibere tumore augmentum.
When the patient’s symptoms cannot be controlled or the scan shows signs of tuberculum growth, further treatment is required, and chemotherapy or targeted drugs (such as sunitinib or everolimus) can be used. For people with poorly differentiated tumors (neuroendocrine carcinoma), chemotherapy is the first choice. For patients who have spread to the liver, choose surgery or ablation technology for treatment according to their own conditions. For adults with somatostatin (a hormone) receptor-positive pancreatic neuroendocrine tumor, the radiopharmaceutical Lutathera (l Lu177 dotatate) is a treatment option.
Si omnes curationes possibiles non iam opus sunt, considera participationem in iudiciis clinicis ad novas therapias probandas. Participatio in iudiciis clinicis est verisimile quibusdam aegris prodesse.
